01—Abstract
Summary
Summary of the 10-K filed February 5, 2025. Cited figures are marked; the original filing is the authoritative source.
3M Company's 2024 10-K filing reveals a pivotal year marked by the significant separation of its Health Care business (Solventum) on April 1, 2024.
This strategic move, while impacting the company's structure and historical reporting, positions 3M to focus on its three core continuing segments: Safety and Industrial, Transportation and Electronics, and Consumer. The company navigated a complex operating environment in 2024, influenced by global economic conditions, geopolitical tensions, and ongoing litigation settlements. Despite these challenges, 3M demonstrated resilience, with efforts to drive productivity, manage costs, and invest in innovation.
The report highlights the company's commitment to shareholder returns through dividends and share repurchases, alongside strategic capital deployment. Key financial and operational considerations for investors include the ongoing impact of litigation settlements, particularly related to PFAS and Combat Arms Earplugs, which continue to represent significant liabilities and affect financial results.
The company's strategic exit from PFAS manufacturing by the end of 2025 is a critical ongoing development. Investors should monitor segment performance, the success of restructuring initiatives, and the company's ability to manage its substantial legal and environmental liabilities while pursuing growth opportunities.
02—Key points
Key Highlights
- Completed the spin-off of its Health Care business (Solventum) on April 1, 2024, leading to a redefined operational structure focused on three core segments: Safety and Industrial, Transportation and Electronics, and Consumer.
- Continued to manage significant financial impacts from litigation settlements, notably the PFAS-related liabilities (PWS Settlement) and Combat Arms Earplugs (CAE Settlement), which represent substantial financial obligations and charges.
- Progressing towards exiting all PFAS manufacturing by the end of 2025, a key strategic initiative impacting the Transportation and Electronics segment.
- Experienced mixed performance across business segments, with the Safety and Industrial segment showing solid operational income growth, while Transportation and Electronics navigated headwinds including PFAS-related impacts.
- Maintained a strong liquidity position, with a significant amount of cash, cash equivalents, and marketable securities, and reduced net debt by approximately $4.9 billion in 2024.
- Returned capital to shareholders through dividends, with a 4% increase in the first-quarter 2025 dividend declared, and significant share repurchases, with $1.8 billion bought back in 2024 under a new $7.5 billion authorization.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2024, 3M Co kept $0.17.
- Revenue$24.57B100.0%
- Cost of revenue−$14.45B58.8%
- Gross profit$10.13B41.2%
- Operating costs−$5.31B21.6%
- Operating income$4.82B19.6%
- Interest, other & tax−$649.0M2.6%
- Net income$4.17B17.0%
Where FY2024 revenue went
$24.57B- Cost of revenue: $14.45B, 59% of revenue
- SG&A: $4.22B, 17% of revenue
- Net income: $4.17B, 17% of revenue
- R&D: $700.0M, 2.8% of revenue
- Other operating costs: $385.0M, 1.6% of revenue
- Interest, other & tax: $649.0M, 2.6% of revenue
Kept 17% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 5, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $24.57B$24.61B | −0.1% |
| Cost of Revenue | $14.45B$14.98B | −3.6% |
| Gross Profit | $10.13B$9.63B | +5.2% |
| R&D Expenses | $700.00M$700.00M | 0.0% |
| SG&A Expenses | $4.22B$19.20B | −78.0% |
| Operating Expenses | $19.75B$35.30B | −44.0% |
| Operating Income | $4.82B-$10.69B | +145.1% |
| Interest Expense | $472.00M$942.00M | −49.9% |
| Net Income | $4.17B-$7.00B | +159.7% |
| EPS (Basic) | $7.58$-12.63 | +160.0% |
| EPS (Diluted) | $7.55$-12.63 | +159.8% |
| Shares Outstanding (Basic) | 550.80M553.90M | −0.6% |
| Shares Outstanding (Diluted) | 552.40M553.90M | −0.3% |
05—Questions
Frequently Asked Questions
What were the key strategic changes impacting 3M in 2024?
The most significant strategic change was the completion of the spin-off of its Health Care business (Solventum) on April 1, 2024. This has allowed 3M to focus on its three core segments: Safety and Industrial, Transportation and Electronics, and Consumer.
What is the current status of 3M's PFAS-related liabilities and manufacturing exit?
3M is committed to exiting all PFAS manufacturing by the end of 2025 and is working to discontinue the use of PFAS across its product portfolio by the same date. The company continues to manage significant legal and environmental liabilities associated with PFAS, including substantial accruals for settlements such as the PWS Settlement. These liabilities are a major ongoing financial consideration.
How did the litigation settlements impact 3M's financial results in 2024?
The company's financial results were significantly impacted by ongoing litigation, particularly the PFAS-related matters and the Combat Arms Earplugs (CAE) settlement. While specific charges were recorded in prior periods for these settlements, the management of these liabilities and related payments continue to affect cash flows and balance sheet reserves. The report notes that significant payments were made in 2024 related to these settlements.
What is the outlook for 3M's business segments?
The Safety and Industrial segment showed resilience and growth in operating income. The Transportation and Electronics segment navigated headwinds, including the impact of PFAS. The Consumer segment saw a slight sales decline but managed operating income. The company's performance is influenced by global economic conditions, consumer spending, and its strategic initiatives like productivity improvements and portfolio management.
06—Continue